Artificial Intelligence
The global pharma R&D outsourcing market is expected to grow at a CAGR of 9.56% during 2022-2027
New York, Sept. 28, 2022 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Pharma R&D Outsourcing Market – Global Outlook & Forecast 2022-2027” – https://www.reportlinker.com/p06320993/?utm_source=GNW
The pharmaceutical R&D outsourcing market is expected to grow as pharmaceutical and biotechnology companies spend more on outsourced services. Outsourced R&D activities span basic research through late-stage development, including genetic engineering, target identification, target validation, assay creation, hit discovery and lead optimization (hit candidates-as-a-service), safety and efficacy assessments in animal studies, and human clinical trials.
MARKET DYNAMICS
Paradigm Shift Towards Virtual Clinical Trials
• Virtual clinical trials or decentralized clinical trials can bring significant digital changes to clinical research methods and enhance the patient-centric ecosystem. These solutions include countless benefits such as technology, advanced applications, electronic devices, online social engagement platforms, artificial intelligence (AI), robotic process automation, and machine learning (ML).
• Patient recruitment is the most prominent cause of clinical delay, followed by significant patient absenteeism. Approximately 30% of phase 3 study discontinuances are said to be due to difficulty recruiting patients. These delays can cost pharmaceutical companies/sponsors up to USD 8 million daily. However, a complete digital or cross model of patient enrolment is employed in decentralized clinical trials. This helps reach the recruitment target easily and rapidly, making the entire process easy, and engaging.
The Emergence of Artificial intelligence (AI) in Drug Discovery & Development
• Artificial intelligence (AI) is used in numerous areas across the world. In healthcare, especially in the pharmaceutical industry, AI is making a notable change as it has varied uses in drug discovery & development, clinical trials, and pharmaceutical productivity. The life cycle of a new drug from a lab to a store is a chain of many complex events that take time and development. Such difficult circumstances can be minimized with the help of AI, and the target can be achieved in a short time.
• Many pharmaceutical companies implement innovative technologies such as AI and machine learning to achieve high-quality results in a short amount of time. In pharmaceutical product development, AI can manage the drug designing, decision making, and therapy determination for patients with personalized medicines; the generated clinical data can be stored for future drug development.
• Global key players from the pharma and biotech industry, such as Eli Lilly Amgen, Merck, LEO, AstraZeneca, Bayer, Novartis, J&J, and BASF, are now a part of machine learning for pharmaceutical discovery.
Increasing Collaboration and partnership among CROs and Stakeholders of the Pharmaceutical Ecosystem
• New models are emerging, and the first innovation comes from the Clinical Research Organization (CRO). CROs establish early chemical / biological entry points for the disease, approach potential interested companies, and collaborate on integrated drug discovery projects that they have identified. Strategic partnerships have long been an essential feature of the pharmaceutical industry. Numerous in-licenses, out-licenses, joint research, and joint development agreements exist between biopharmaceutical companies and academic research institutes.
• In recent years, several significant outsourcing partnerships were done, such as the UK-based AstraZeneca partnering with academic organizations, the Cambridge University, focusing on drug development. It partnered with the University of Texas MD Anderson Cancer Center in the United States to develop immunotherapy.
Some of the examples of significant strategic partnerships of outsourcing are:
a) Allied Minds & Bristol-Myers Squibb
b) GSK & University of Leicester
c) Actelion Pharmaceuticals & Enamine
SEGMENTATION ANALYSIS
The pharma R&D outsourcing market is segmented on the product, stage of development, size of companies, therapy areas, and geography.
Insights by Product
Among all products, the small molecules segment reported a significant pharma R&D outsourcing market share. The small molecules segment is estimated to be higher because small molecules are likely to play a crucial part in easing the burden of chronic disease. This diverse group of small chemical compounds offers many benefits for scientists and researchers:
a) They have a wide-ranging use.
b) They are comparatively low in cost.
c) They allow for easy administration, including an oral route of administration.
d) They can pass within cell membranes to achieve their targets due to their small size.
e) They provide consistent results.
Pharmaceutical companies planning small molecule clinical studies need to work with the appropriate contract research organization (CRO) to conduct valuable research using reliable data. The food and Drug Administration (FDA) approved 50 novel drugs in 2021. 36 are small molecules which is 72% of the total approval of pharmaceutical drugs by the FDA.
Segmentation by Product Type
• Small Molecules
• Biologics
Insights by Stage of development
a) Among stages of development, the clinical segment reported a major share of around 64.13% in 2021. The clinical segment is estimated to be higher because, according to World Health Organization (WHO), approximately 47,689 clinical trials are in Phase I. The high number of clinical trials in phase 1 is highly outsourced. In outsourcing well-established data about patient recruitment, activities of clinical trials related to phase 1 and other procedures such as analysis and documentation are the easy thing done in the phase.
b) Phase 1 clinical trials required more than USD 30 million in capital investment. Compounds in oncology, respiratory diseases, and other therapeutic areas require a lot of money. Around 70% of drugs move from Phase I to the next phase states by US FDA.
c) Phase II can last for several years; as per the WHO, around 88,530 compounds in phase 2 clinical trials till 2022. As per US FDA, approximately 33% of new drugs are moved from phase II to the next.
d) The number of subjects usually ranges from hundreds to about 3,000. If the FDA agrees that the study results are positive, the FDA will approve the experimental drug or equipment. As per the WHO, around 68,999 drugs came to phase III till 2022. In this phase, doctors, physicians, or professionals do not know whether the treatment is better, so random participants are picked up to get the approval for new treatment and sent into the next phase. This procedure is often done in many places across the region/world at the same time to analyze the efficacy of drugs in different geography and demography.
Segmentation by Stage of Development
• Clinical
• Non-Clinical
Insights by Size of Company
a) Among the size of the company, the small & mid-sized companies segment reported a major share of around 57.54% in 2021. The small & mid-sized companies market segment is estimated to be higher because, in 2019, the emerging therapeutic companies (ETC) were responsible for 73% (5,067 of 6,984) of global industrial, and pharmaceutical projects at all clinical stages, either alone or in collaboration with partners, with the rest being carried out by large companies.
b) SMEs will account for 71%, 76%, 68%, and 62% of Phase I, II, III, and new drug applications, respectively, compared to large companies. 45% of all clinical ETC pipeline projects are carried out in collaboration with other partners. Oncology is the main disease focus of these SME clinical projects.
c) In 2018, the Market researcher identified that 74 small pharmaceutical companies have total sales of $159 billion and 446 pharmaceuticals drugs in their R&D pipeline, 9 medium-sized companies with sales of $50 billion and 181 products, and sales of $139 billion in the R& D pipeline.
d) A 2017 BIO industry analysis shows that small biotechnology companies are responsible for 70% of all bio pharmacy clinical trials worldwide, representing 6,679 programs, 43% of which partner with other companies. It was carried out. Large companies conducted the remaining 30% of these clinical trials.
Segmentation by Company Size
• Small & Mid-Sized Companies
• Large Companies
Insights by Therapy Areas
a) Among therapy areas, the oncology segment reported a major share of around 30.71% in 2021. The oncology segments are estimated to be higher because there are 19.3 million new cancer instances and approximately 10 million fatalities worldwide in 2020, accounting for nearly one out of every six deaths as per Globocan 2020 report.
b) Oncology is one of the most dominant therapy areas for industry and non-industry-sponsored clinical trials. The rising prevalence of cancer conditions significantly contributed to oncology therapeutic area clinical trials. Changing the paradigm for testing cancer treatment in the world increased the global efforts toward generating evidence for oncology clinical trials.
c) In 2019 only around 30 FDA approvals were registered for chemotherapeutic drugs. In the US, about 361,628 clinical trials have been reported only for cancer in the past 20 years. Cancer clinical trial drug development activities increased significantly, leading to increased clinical trial volume.
d) Global spending on anticancer medications climbed by 14.3% in 2020, reaching $164 billion. Spending is expected to reach $269 billion by 2025. The high prices of novel anticancer medicines drive much of this growth. The direct and indirect expenses of oncological treatments severely affect patients’ treatment success and financial well-being worldwide.
e) In the US, around 361,628 clinical trials registered only for cancer in the past 20 years. Cancer clinical trial drug development activities increased significantly, leading to increased clinical trial volume.
Segmentation by Therapy Area
• Oncology
• Cardiovascular Diseases
• Infectious Diseases
• Musculoskeletal Disorders
• Central Nervous System Disorders
• Gastrointestinal Disorders
• Other Therapy Areas
GEOGRAPHY ANALYSIS
The North America region reported a significant share of around 36.23% in 2021. The North America region is estimated to be higher because considerable investment by companies in R&D to strengthen the pipeline for chronic diseases is projected to boost the launch of novel therapeutics in North America. North America witnesses prominent start-up CROs working in the pharmaceutical R&D outsourcing market. The region also saw collaborations and partnerships among the pharmaceutical ecosystem’s stakeholders.
Segmentation by Geography
• North America
o US
o Canada
• Europe
o Germany
o UK
o France
o Italy
o Spain
• APAC
o China
o Japan
o India
o Australia
o South Korea
• Latin America
o Brazil
o Mexico
o Argentina
• Middle East & Africa
o South Africa
o Saudi Arabia
o Turkey
o UAE
VENDOR ANALYSIS
Vendors in the pharma R&D outsourcing market compete based on the wide range of services offered, quality, and scale-up development of pharmaceuticals. The market is so competitive that vendors aim to implement different strategies to maintain their competitive advantage over other vendors. The market players focus on acquisitions, partnerships, diversifying their outsourcing services, and strengthening their distribution networks to increase their market share. There are around 33 vendors in the pharmaceutical R&D outsourcing market, including key players and other prominent players.
Key Vendors
• Charles River Laboratories
• ICON
• IQVIA
• Labcorp Drug Development
• Medpace
• Parexel International Corporation
• Syneos Health
• Thermo Fisher Scientific
• Wuxi AppTec
• Lonza
• Boehringer Ingelheim
• Samsung Biologics
Other Prominent Vendors
• AbbVie
• Advanced Clinical
• BioAnalytix
• Asymchem
• Alcami
• Bavarian Nordic
• Catalent
• Curia Global
• ChemPartner
• CMED
• Criterium
• Cromos Pharma
• Evotec
• Jubilant HollisterStier
• KBI Biopharma
• KCR S.A.
• Kemwell Biopharma
• Mesned Pharma Consult Center
• Midas Pharma
• Medelis
• Merck KGaA
• OCT Clinical
• Pharmaceutics International
• ProTrials Research
• PROMETRIKA
• QPS
• Singota Solutions
• Sofpromed
• Sanofi
• Taros chemicals
• Veristat
• Worldwide Clinical Trials
• WuXi Biologics
• Wacker Biotech B.V
KEY QUESTIONS ANSWERED
1. How big is the pharmaceutical R&D outsourcing market?
2. What is the growth rate of the global pharmaceutical R&D outsourcing market?
3. Who are the key players in the global pharma R&D outsourcing market?
4. Which geographical region leads in the pharma R&D outsourcing market?
5. What are the growth factors in the global pharmaceutical R&D outsourcing market?
Read the full report: https://www.reportlinker.com/p06320993/?utm_source=GNW
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.
__________________________
SALT LAKE CITY, May 13, 2024 /PRNewswire/ — MasterControl, a leading provider of manufacturing and quality management software solutions for regulated industries, is excited to announce the launch of their latest product, MasterControl Logbooks. This innovative electronic logbook software solution aims to revolutionize traditional paper-based log management, bringing increased compliance, efficiency, and data integrity to quality and manufacturing processes.
Logbooks play a crucial role in documenting every significant step in the manufacturing and quality assurance journey, from R&D to production. However, traditional paper logbooks often present challenges in terms of maintaining data integrity and operational efficiency. The MasterControl Logbooks solution addresses these issues by offering a fully digital platform that allows organizations to seamlessly build, issue, execute, and review logbooks electronically, ensuring maximum efficiency and compliance with current good manufacturing practices (cGMP).
Streamlined log management is one of the transformative benefits the MasterControl Logbooks solution provides. With an intuitive drag-and-drop template builder, users can easily create customizable logbooks tailored to their specific needs. The cloud-based nature of MasterControl Logbooks enables easy access and review from anywhere, at any time. This eliminates the hassle of misinterpreting or losing logbooks information, as all current and archived logbooks are stored in a simple list view with advanced search functionality to quickly pinpoint specific logbooks, even down to the entry.
In addition to streamlined log management, MasterControl Logbooks also enhances quality control. Robust permissions management functionality ensures that users only see and launch logbooks that are relevant to their responsibilities. The solution also offers features such as training checks, mandatory fields, and correction logs that enhance traceability and data integrity.
“With MasterControl Logbooks, all your documents are in one place instead of on hundreds and hundreds of pages scattered throughout the plant,” said Pine Pharmaceuticals IT System Administrator Robert Mansell. “The interface is easy to use, and the design is so simple it’s scary. Everything you need is right on screen, but if you do need something else the links are all right there.”
“Our goal with MasterControl Logbooks is to transform and optimize the way logbooks are managed in regulated industries,” said MasterControl CEO Jon Beckstrand. “By providing an innovative and user-friendly electronic logbook software solution, we can help our customers greatly enhance efficiency, data integrity, and compliance.”
MasterControl prides itself on its expertise in providing software solutions for regulated industries. Since it was established in 1993, the company’s commitment to innovation and customer satisfaction has made them a trusted partner for organizations looking to streamline their quality and manufacturing processes. With MasterControl Logbooks, they continue to lead the way in digital transformation for regulated industries.
For more information about MasterControl Logbooks and its features, please visit www.mastercontrol.com/logbooks.
About MasterControl:
MasterControl Inc. is a leading provider of cloud-based software solutions that enable regulated companies to deliver life-changing products to more people sooner. MasterControl’s manufacturing and quality management software solutions help organizations innovate faster, reduce costs, and improve compliance by automating and securely managing critical business processes throughout the entire product life cycle. For more information, visit www.mastercontrol.com.
Logo – https://mma.prnewswire.com/media/2391672/MasterControl_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/mastercontrol-launches-innovative-electronic-logbook-software-solution-302142725.html
Artificial Intelligence
BelindaCZ s.r.o. Introduces Notepad++ 8.6.5 Pre-installed on Windows Server 2022
PRAGUE, May 13, 2024 /PRNewswire/ — BelindaCZ s.r.o. is excited to announce a significant enhancement for developers working on Windows Server 2022. The latest version of Notepad++ (version 8.6.5) is now pre-installed on Windows Server 2022, providing a seamless and powerful coding environment right out of the box.
Why This Matters:
Tailored for Developers: With Notepad++ pre-installed, Windows Server 2022 offers an optimized platform for developers who require a reliable and robust text/source code editor.
Intuitive and Customizable: Notepad++ features an intuitive interface and powerful tools like syntax highlighting and code folding, designed to enhance productivity.
Advanced Plugin Support: The extensive plugin support allows developers to customize and enhance their workflow, ensuring efficient coding in multiple programming languages.
About Notepad++:
Notepad++ is a free, open-source text and source code editor known for its lightweight design and high efficiency. It is beloved by developers for its advanced features, including syntax highlighting, code folding, and extensive plugin support. Notepad++ has become an indispensable tool for programmers and text editors alike.
Ready to explore the possibilities? Discover the enhanced coding experience with Notepad++ pre-installed on Windows Server 2022.
About BelindaCZ s.r.o.:
BelindaCZ s.r.o. is a leading provider of innovative IT solutions, committed to empowering businesses with advanced technology. Specializing in cloud computing and IT infrastructure, BelindaCZ s.r.o. delivers comprehensive services to clients globally.
www.belinda-cz.com
Photo – https://mma.prnewswire.com/media/2409618/Notepad_Windows_Server.jpg
View original content:https://www.prnewswire.co.uk/news-releases/belindacz-sro-introduces-notepad-8-6-5-pre-installed-on-windows-server-2022–302143398.html
STOCKHOLM, May 13, 2024 /PRNewswire/ — The shareholders in SciBase Holding AB (publ), reg. no. 556773-4768 (the “Company”), are hereby given notice to attend the annual general meeting at 15:00 p.m. on Thursday 13 June 2024 at Setterwalls Advokatbyrå’s offices at address Sturegatan 10 in Stockholm. Registration for the meeting commences at 14:45 p.m. The board of directors has decided, pursuant to Chapter 7, Section 4a of the Swedish Companies Act and the Company’s articles of association, to apply the possibility of postal voting in conjunction with the general meeting (see “Postal voting” below for more information).
Notice
Shareholders wishing to participate at the meeting must:
be entered in the shareholders’ register, kept by Euroclear Sweden AB (the Swedish Central Securities Depository & Clearing Organisation), on the record day, which is Tuesday 4 June 2024, andnotify the Company of their attendance and any assistant no later than Friday 7 June 2024. Notification can be made in writing to Setterwalls Advokatbyrå AB, Attn: Eric Torstensson, P.O. Box 1050, SE-101 39 Stockholm, Sweden or by e-mail to [email protected] shall include full name, personal identification number or corporate registration number, address, daytime telephone number and, if appropriate, information about representative, proxy, and assistants. The number of assistants may not be more than two. In order to facilitate entry to the meeting, notification should, where appropriate, be ac-companied by powers of attorney, registration certificates and other documents of authority.
Nominee registered shares
In order to be entitled to participate and vote at the meeting, shareholders who have their shares registered in the name of a nominee must have their shares registered in their own name, so that the shareholder will be included in the transcription of the share register as of Tuesday 4 June 2024. Such registration may be temporary (so-called voting rights registration) and is requested to the nominee in accordance with the nominee’s routines at such time in advance as the nominee determines. Voting rights registrations made by the nominee no later than Friday 7 June 2024 will be taken into account in the preparation of the share register.
Postal voting
The board of directors has decided, pursuant to Chapter 7, Section 4a of the Swedish Companies Act and the Company’s articles of association, to apply the possibility of postal voting in conjunction with the general meeting. A special form shall be used for postal voting. The form will be available on the Company’s website, https://investors.scibase.se/en/governance/annual-general-meeting.
The form may be submitted by post to Setterwalls Advokatbyrå AB, Attn: Eric Torstensson, P.O. Box 1050, 101 39 Stockholm or via e-mail to [email protected]. The completed voting form must be received by Setterwalls Advokatbyrå AB no later than Wednesday 12 June 2024 provided the shareholder has given notice of attendance at the general meeting no later than Friday 7 June 2024. However, a complete postal vote which reaches Setterwalls Advokatbyrå AB no later than Friday 7 June 2024 shall also be considered the shareholder’s notice of attendance at the meeting (by postal voting).
The shareholder may not provide special instructions or conditions in the voting form. If so, the vote (i.e. the postal vote in its entirety) is invalid. Further instructions and conditions are included in the form for postal voting.
Proxy voting
A shareholder represented by proxy shall issue a power of attorney which shall be dated and signed by the shareholder. If the shareholder postal votes by proxy, the power of attorney shall be enclosed to the form. If issued by a legal entity, the power of attorney shall also be accompanied by registration certificate or, if not applicable, equivalent documents of authority. Power of attorney forms will be available on the Company’s website https://investors.scibase.se/en/annual-general-meeting-2024.
Processing of personal data
For information regarding how your personal data is processed in connection with the annual general meeting, please refer to the privacy policy on Euroclear Sweden AB’s website, https://www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf.
Proposed agenda
Opening of the meeting and election of chairman of the meeting.Preparation and approval of the voting list.Approval of the agenda.Election of one person who shall approve the minutes of the meeting.Determination of whether the meeting has been duly convened.Submission of the annual report and the auditor’s report as well as of the consolidated financial statements and the auditor’s report on the group.Resolution in respect of:adoption of the profit and loss statement and the balance sheet as well as of the consolidated profit and loss statement and the consolidated balance sheet; allocation of the Company’s results according to the adopted balance sheet; andthe members of the board of directors’ and the CEO’s discharge from liability.Resolution regarding the number of members and, where applicable, deputies of the board of directors and number of auditors and, where applicable, deputy auditors.Determination of the fees payable to the members of the board of directors and the auditors.Election of members of the board of directors and auditor.Resolution on principles for the appointment of a nomination committee.Resolution on an authorisation for the board of directors to resolve upon issues of shares, warrants and convertibles.Closing of the meeting.The nomination committee’s proposed resolutions
The nomination committee is composed of the chairman of the board of directors of the Company (i.e. Tord Lendau), Thomas Axelsson (appointed by Gell Group), Dharminder Chahal (appointed by VanHerk Group), and Peter Elmvik (appointed by Stockholms Elbolag). The nomination committee has presented the following proposed resolutions in relation to items 1 and 8-11 in the proposed agenda.
Item 1 – Election of chairman
Axel Helle (lawyer at Setterwalls Advokatbyrå AB) is proposed as chairman of the meeting, or if he is unable to attend the meeting, any other person proposed by the board of directors.
Items 8-10 – Resolution regarding the number and election of and remuneration to the board of directors and auditors
The nomination committee proposes that the board of directors, until the end of the next annual general meeting, shall consist of four (4) ordinary members without deputy members. Furthermore, it is proposed that a registered accounting firm shall be elected as auditor.
The nomination committee furthermore proposes that the fees payable to the board of directors for the period until the end of the next annual general meeting shall be SEK 200,000 for the chairman of the board and SEK 150,000 to each of the other ordinary board members (who are not employed by a larger shareholder in the Company). It is proposed that the Company’s auditor shall be paid in accordance with approved invoices.
The board of directors today consists of the following five (5) ordinary members without deputy members: Tord Lendau (chairman), Diana Ferro, Thomas Taapken, Matt Leavitt och Jvalini Dwarkasing.
Tord Lendau has declined re-election after ten years as chairman of the board of directors. Matt Leavitt and Jvalini Dwarkasing have also declined re-election. However, Matt Leavitt will continue to assist the Company on a consultancy basis.
The nomination committee proposes that Diana Ferro and Thomas Taapken are re-elected and that Jesper Høiland and Robert Molander are new-elected as ordinary board members. Furthermore, Jesper Høiland is proposed to be new-elected as chairman of the board of directors.
The registered accounting firm PricewaterhouseCoopers AB (PwC) is proposed to be re-elected as auditor. The accounting firm has informed that Magnus Lagerberg will remain as principally responsible auditor.
The nomination committee has, as the basis for its proposal, regarding the composition of the board of directors, discussed the Company’s future needs and reviewed the annual evaluation of the board of directors and its work and interviewed several candidates. The nomination committee has thoroughly discussed the requirements for competence, experience and background that are placed on the board of directors of Scibase, considering, among other things, the Company’s strategic development, governance and control. Independence issues have been highlighted, as well as the requirement for versatility and breadth in the board. The nomination committee makes the assessment that the proposed board members, considering the Company’s needs, operations, stage of development and other circumstances, would give the board of directors a good and appropriate composition.
Below is a summarized description of the proposed new board members’ education, experience, other assignments, and independence. Further information about all proposed board members will be made available on the Company’s website.
Jesper Høiland
Education: MSc and BSc, Copenhagen Business School.
Experience: Jesper has over 25 years of experience from senior positions in global pharmaceutical companies such as Ascendis Pharma (CCO), Radius Health (CEO) and Novo Nordisk (President and EVP for the US with a particular focus on pricing, product launches and infrastructure building). Jesper has previously been a board member of Concert Pharma and Leo Pharma. Jesper has lived and worked in the US, Switzerland, Denmark, Australia, France, Belgium and Canada for the past 30 years.
Other current assignments: Strategic advisor to pharmaceutical and medical device companies. Member of the board of directors and the audit committee of ALK.
Independence: Jesper is independent in relation to the Company and its management as well as to major shareholders.
Robert Molander
Education: MBA in Marketing and Finance, Washington University, John M. Olin School of Business and dual BA degrees in Economics and International Studies, Miami University.
Experience: Senior executive and advisor with over 25 years of expertise in life science commercialization, primarily based in the United States. Robert has successfully led companies such as Novartis, Pfizer, Shionogi, and Trialbee through product launches, business development and scaling commercial operations. Robert has previously been Chief Commercial Officer at Infant Bacterial Therapeutics AB and Trialbee AB and a board member of Infant Bacterial Therapeutics AB.
Other current assignments: Board member of Xspray Pharma AB, CEO of Stratfox Healthcare Group LLC.
Independence: Robert is independent in relation to the Company and its management and to major shareholders.
Item 11 – Resolution on principles for the appointment of a nomination committee
The nomination committee proposes the following decision for appointment of a nomination committee for the annual general meeting 2025 (same principles as the previous year). The nomination committee for the annual general meeting 2025, which shall be comprised of four members, shall be appointed by way of that the chairman of the board of directors will consult with the three largest shareholders of the Company at the end of the third quarter of 2024. These shareholders will be requested to each appoint one member who, together with the chairman of the board of directors, will form the nomination committee. The composition of the nomination committee shall be publicly announced no later than six months prior to the annual general meeting. The nomination committee, whose mandate period applies until the time a new nomination committee has constituted itself, shall appoint a chairman among its members. The nomination committee shall prior to the annual general meeting 2025 prepare and submit proposals regarding the election of the chairman of the annual general meeting, the number of board members and, where applicable, deputy members, the number of auditors and, where applicable, deputy auditors, the election of board members, chairman and, where applicable, deputy members, auditor and, where applicable, deputy auditors, remuneration for the board of directors and the auditor, as well as guidelines for the appointment of the nomination committee for the following annual general meeting. The nomination committee’s proposals shall be presented in the notice to a general meeting where election of board members and auditor shall take place and on the Company’s website. Should a member of the nomination committee resign from its assignment, a replacement shall be sought from the shareholder that appointed the departing member. Should a shareholder that has appointed a member of the nomination committee substantially decrease its ownership in the Company, the next shareholder in size order shall, if the nomination committee so resolves, be requested to appoint a member to the nomination committee.
The board of directors’ proposed resolutions
The board of directors of the Company has presented the following proposed resolutions in relation to items 7(ii), and 12 in the proposed agenda.
Item 7 (ii) – Allocation of the Company’s results according to the adopted balance sheet
The board of directors proposes that SEK 202,523,429 shall be carried forward in new account. Accordingly, no dividend is proposed.
Item 12 – Resolution regarding authorisation for the board of directors to resolve upon issues of shares, warrants and convertibles
The board of directors proposes that the annual general meeting resolves to authorize the board of directors to, until the next annual general meeting, on one or more occasions, decide upon issuances of new shares, issuance of warrants and/or convertibles. New issues of shares and issues of warrants and/or convertibles may occur with or without preferential rights for shareholders of the Company and may be made either in cash and/or by way of set-off or contribution in kind or otherwise be conditional. Through issuances resolved upon with support from the authorisation – with deviation from the shareholders’ preferential rights – the number of shares issued, or number of shares created in connection with exercise of warrants or conversion of convertibles, shall correspond to not more than a 20 per cent dilution of the share capital and the number of shares and votes in the Company after such issue(s). The chairman of the board of directors, the CEO or a person appointed by the board of directors shall be authorized to make any minor adjustments required to register the resolution with the Swedish Companies Registration Office.
Majority requirements
Resolution in accordance with the board of director’s proposal in accordance with item 12 on the agenda requires that the general meeting’s resolution is supported by shareholders representing at least two thirds of the shares represented at the general meeting as well as of the votes cast.
Shareholders’ right to request information
The board of directors and the CEO shall, if any shareholder so requests and the board of directors believe that it can be done without material damage to the Company, provide information regarding circumstances that may affect the assessment of an item on the agenda, of the Company’s, or a subsidiary’s economic situation and of the Company’s relations with other group companies on the general meeting.
Documentation
The financial accounts and auditor’s report will be kept available at the Company’s office and on the Company’s website www.scibase.com. Copies of such documents will be sent free of charge to shareholders who so request and state their postal address. The proposals of the board of directors and the nomination committee are set out in full in the notice.
Stockholm, May 2024SciBase Holding AB (publ)The board of directors
For more information, please contact:Pia Renaudin, CEO SciBaseTel: +46 73 206 98 02Email: [email protected]
Certified Adviser: Vator SecuritiesTel: +46 8 580 065 99Email: [email protected]
The information was submitted, through the agency of the contact person set out above, for publication at the time stated by Scibase’s news distributor Cision upon publication of this press release
About SciBase
SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015. Learn more at www.scibase.com. All press releases and financial reports can be found here: https://investors.scibase.se/en/pressreleases.
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/scibase/r/notice-to-attend-the-annual-general-meeting-in-scibase-holding-ab–publ-,c3977598
The following files are available for download:
https://mb.cision.com/Main/12371/3977598/2790717.pdf
SciBase Holding AB (publ) – Notice to attend AGM 2024 (ENG)
View original content:https://www.prnewswire.co.uk/news-releases/notice-to-attend-the-annual-general-meeting-in-scibase-holding-ab-publ-302143390.html
-
Artificial Intelligence7 days agoSolar EV Charging to Bypass the Grid: A US$2.5 Billion Market by 2034, Says IDTechEx
-
Artificial Intelligence5 days agoKörber Pharma and Siemens Take the Lead in ABI Research’s MES Software for Pharmaceutical, Biotechnology, and Cell & Gene Manufacturing Competitive Ranking
-
Artificial Intelligence5 days agoNew Momentum in Pharma Automation: ArisGlobal’s 2024 Industry Survey Report Highlights Surge in AI-Powered Safety & Regulatory Processes
-
Uncategorized5 days agoSmart Waste Management Market to Reach $8.3 billion by 2032 at 15.6% CAGR: Allied Market Research
-
Artificial Intelligence5 days agoNess Digital Engineering Acquires Intricity – a New York based company specializing in data strategy, governance, modernization, and monetization
-
Artificial Intelligence3 days agoSanad Announces Strategic Sale Transaction with CFM Materials, Further Fostering Aviation Industry Collaborations
-
Artificial Intelligence3 days agoNorthern Data Group’s Peak Mining announces new partnership for 28MW of mining, powered by 100% renewable energy
-
Artificial Intelligence6 days agoImaging Endpoints Unveils New Initiative with Revolution Endpoints™, an Investment Subsidiary to Accelerate Innovation and Growth
